Covid-19 Vaccination

Changing the way the world ages

YTB Healthcare Sdn Bhd has formalized its collaboration with China’s Shenzhen Kangtai Biological Products Co Ltd by entering into a definitive agreement for the phase III clinical trials and commercialization of the latter’s Covid-19 Vaccine. This virtual signing ceremony was witnessed by YB Senator Tuan Jaziri Alkaf Abdillah Suffian and Chief Executive Officer of Clinical Research Malaysia Dr. Akhmal Yusof.

Yong Tai has also signed a service agreement with BCA international Sdn Bhd which was represented by Mazlizza Mahdzar, its Managing Director.

The Signed agreement demonstrates SZKT pharmaceuticals’ confidence in the delivery capabilities of Yong Tai Group. Yong Tai Group will be continuing to explore cooperation opportunities with SZKT or other pharmaceutical companies to bring other types of vaccines to Malaysia. Yong Tai will be the first private company to initiate and sponsor the trials to be done in Malaysia with the Guidance and assistance from experts such as Clinical Research Organisation (CRO) and Clinical Research Malaysia (CRM) therefore the help Malaysia to achieve herd immunity soonest possible so that people’s daily lives can get back to normal, as well as the country’s economy activities shall recover.